Investigating pulmonary blood flow during exercise

Pulmonary Hemodynamics During Exercise - Research Network

This study is testing how blood flow in the lungs during exercise affects the health and outcomes of people with lung circulation problems.

Quick facts

• Study type: Observational
• Enrollment: 1500 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Medical University of Graz (Academic / other)
• Locations: 32 sites (Phoenix, Arizona and 31 other locations)
• Trial ID: NCT03954574 on ClinicalTrials.gov

What this trial studies

This clinical research collaboration aims to explore the prognostic implications of pulmonary hemodynamics during exercise through a large-scale multi-center approach. The study will utilize both retrospective and prospective analyses of hemodynamic data collected from patients undergoing right heart catheterization. By assessing pulmonary blood flow during physical activity, the research seeks to better understand the impact of pulmonary circulation diseases on patient outcomes.

Who should consider this trial

Good fit: Ideal candidates include adults over 18 with intermediate or high echocardiographic probability of pulmonary hypertension and/or unexplained dyspnea.

Not a fit: Patients with advanced tumor diseases, severe heart failure, or significant respiratory limitations may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved prognostic assessments and treatment strategies for patients with pulmonary circulation diseases.

How similar studies have performed: Other studies have shown promise in understanding pulmonary hemodynamics, but this approach may provide novel insights due to its multi-center design.

Eligibility criteria

Inclusion Criteria:

* Patients (females and males; age: above 18yrs) with intermediate or high echocardiographic probability of PH and/or unexplained dyspnea, and/or associated conditions for PAH as clinical indication for RHC at rest and exercise
* Written informed consent of participating subjects after being fully briefed (for prospective analysis)

Exclusion Criteria:

* Patients with incomplete hemodynamic data at rest or exercise
* Patients without sufficient follow-up data (information on survival / lung transplantation)
* advanced tumour disease or other diseases with a short life expectancy, except pulmonary vascular diseases
* advanced heart failure with pulmonary arterial wedge pressure (PAWP) \> 18 mmHg at rest
* uncontrolled systemic arterial hypertension (RR values \> 160/100 mmHg at rest)
* FEV1\<50% predicted
* TLC\<60% predicted

Where this trial is running

Phoenix, Arizona and 31 other locations

• University of Arizona, Banner University Medical Center — Phoenix, Arizona, United States (Recruiting)
• University of California, Los Angeles, Lung & Heart-Lung Transplant and Pulmonary Hypertension Programs, David Geffen School of Medicine — Los Angeles, California, United States (Recruiting)
• Johns Hopkins Hospital, Advanced HF, MCS, Transplant Cardiology, Baltimore, Maryland, USA — Baltimore, Maryland, United States (Recruiting)
• Massachusetts General Hospital, Cardiology Division and Pulmonary Unit — Boston, Massachusetts, United States (Recruiting)
• Harvard Medical School, Brigham and Women's Hospital — Boston, Massachusetts, United States (Recruiting)
• University of Minnesota Medical School, Division of Cardiology, Department of Medicine, Lillehei Heart Institute Minneapolis, Minnesota, USA — Minneapolis, Minnesota, United States (Recruiting)
• Mayo Clinic, Division of Cardiovascular Diseases, Department of Medicine — Rochester, Minnesota, United States (Recruiting)
• Medical University of South Carolina — Charleston, South Carolina, United States (Recruiting)
• Royal Prince Alfred Hospital, Respiratory Medicine — Camperdown, Australia (Recruiting)
• Medical University of Graz — Graz, Austria (Recruiting)
• Free University of Brussels, Faculty of Medicine, Physiology — Brussels, Belgium (Recruiting)
• University of São Paulo Medical School — São Paulo, Brazil (Recruiting)
• Department of Cardiology, Aarhus University Hospital, Denmark — Aarhus, Denmark (Recruiting)
• Université de Lorraine — Nancy, France (Recruiting)
• Centre Chirurgical Marie Lannelongue, Thoracic and Vascular Surgery — Paris, France (Recruiting)
• Centre de Référence de l'Hypertension Pulmonaire, Université ParisSud - Université Paris-Saclay, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris — Paris, France (Recruiting)
• Sorbonne Universités, Neurophysiologie respiratoire expérimentale et clinique — Paris, France (Recruiting)
• University of Cologne, Klinik III fuer Innere Medizin — Cologne, Germany (Recruiting)
• Justus-Liebig-University Giessen, Department of Internal Medicine — Giessen, Germany (Recruiting)
• University of Greifswald — Greifswald, Germany (Recruiting)
• Thorax Clinic Heidelberg, Centre for Pulmonary Hypertension — Heidelberg, Germany (Recruiting)
• Academic Teaching Hospital of the Julius Maximilian University of Würzburg — Würzburg, Germany (Recruiting)
• University of Bologna — Bologna, Italy (Recruiting)
• University of Rome La Sapienza, Cardiovascular and Respiratory Sciences — Roma, Italy (Recruiting)
• VU Medisch Centrum, Pulmonology — Amsterdam, Netherlands (Recruiting)
• Otwock Medical Center of Postgraduate Education, Department of Pulmonary Circulation and Thromboembolic Diseases — Otwock, Poland (Recruiting)
• Barcelona Hospital Clínic, Pneumologia — Barcelona, Spain (Recruiting)
• University Hospital of Zurich, Internal Medicine — Zurich, Switzerland (Recruiting)
• Scottish Pulmonary Vascular Unit — Glasgow, United Kingdom (Recruiting)
• Imperial College, NHS Healthcare NHS Trust, National Pulmonary Hypertension Service — London, United Kingdom (Recruiting)
• Royal Brompton Hospital — London, United Kingdom (Recruiting)
• Royal Hallamshire Hospital, Sheffield Pulmonary Vascular Disease Unit — Sheffield, United Kingdom (Recruiting)

Study contacts

• Study coordinator: Gabor Kovacs, MD

Conditions Pulmonary Circulation Diseases